Carcinomas News and Research RSS Feed - Carcinomas News and Research

Study compares five-year DFS and OS rates for patients with AIS and MIA

Study compares five-year DFS and OS rates for patients with AIS and MIA

Lung cancer patients with minimally invasive adenocarcinoma (MIA) have similar, positive five-year disease-free survival (DFS) and overall survival (OS) rates as patients with adenocarcinoma in-situ (AIS), according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. [More]
Molecular profiling reveals potential therapeutic targets for lung cancer

Molecular profiling reveals potential therapeutic targets for lung cancer

Analysis of 607 small cell lung cancer (SCLC) lung tumors and neuroendocrine tumors (NET) identified common molecular markers among both groups that could reveal new therapeutic targets for patients with similar types of lung cancer, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. [More]
TNF-α key player in RCC progression

TNF-α key player in RCC progression

Tumour necrosis factor - α appears to play a key role in the promotion of invasion and metastasis in clear cell renal cell carcinomas, Japanese study findings indicate. [More]
KU researchers find potential therapeutic target for triple-negative breast cancer

KU researchers find potential therapeutic target for triple-negative breast cancer

A team at the University of Kansas School of Medicine has identified a potential target for treating breast cancer, including a particularly deadly form of the disease. [More]
Study reveals subtypes, potential diagnostic and treatment clues for papillary thyroid carcinomas

Study reveals subtypes, potential diagnostic and treatment clues for papillary thyroid carcinomas

A comprehensive analysis of the genomes of nearly 500 papillary thyroid carcinomas (PTC) – the most common form of thyroid cancer – has provided new insights into the roles of frequently mutated cancer genes and other genomic alterations that drive disease development. [More]
Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen Research & Development, LLC today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) to the U.S. Food and Drug Administration by its strategic partner Pharmacyclics, Inc. [More]
Testosterone therapy raises risk of prostate tumors in rats

Testosterone therapy raises risk of prostate tumors in rats

A researcher who found that testosterone raised the risk of prostate tumors and exacerbated the effects of carcinogenic chemical exposure in rats is urging caution in prescribing testosterone therapy to men who have not been diagnosed with hypogonadism, according to a new study published in the Endocrine Society's journal Endocrinology. [More]
Scientists identify new biomarker for diagnosing cause of thyroid cancer

Scientists identify new biomarker for diagnosing cause of thyroid cancer

The expression of the protein CLIP2 provides information on whether a papillary thyroid carcinoma was induced by radiation or had a sporadic origin. With this discovery, scientists from the Helmholtz Zentrum München have identified a new biomarker for the diagnosis of the cancer cause. [More]
Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC). [More]
Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain. [More]
Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show. [More]
Genetic mutation caused by ultraviolet light is likely driving force behind human skin cancers

Genetic mutation caused by ultraviolet light is likely driving force behind human skin cancers

A genetic mutation caused by ultraviolet light is likely the driving force behind millions of human skin cancers, according to researchers at the Stanford University School of Medicine. [More]
KIT spinoff amcure develops tumor therapeutic agents to reduce mortality rate

KIT spinoff amcure develops tumor therapeutic agents to reduce mortality rate

There is an urgent need for medical agents to treat metastatic tumors. In case of pancreatic cancer, one of the most aggressive types of cancer that is often detected late, 95% of the patients die within five years after the diagnosis. [More]
US lung cancer rates uncover trends related to cancer subtype, sex, race/ethnicity and age

US lung cancer rates uncover trends related to cancer subtype, sex, race/ethnicity and age

A new analysis confirms that US lung cancer rates are declining overall, but it also uncovers previously unrecognized trends related to cancer subtype, sex, race/ethnicity, and age. [More]
Research points to new direction for potential therapies to treat mucoepidermoid carcinoma

Research points to new direction for potential therapies to treat mucoepidermoid carcinoma

Research conducted at the Florida campus of The Scripps Research Institute has discovered links between a set of genes known to promote tumor growth and mucoepidermoid carcinoma, an oral cancer that affects the salivary glands. The discovery could help physicians develop new treatments that target the cancer's underlying genetic causes. [More]
Montefiore-Einstein investigators to present new findings from eight abstracts at IFHNOS 2014

Montefiore-Einstein investigators to present new findings from eight abstracts at IFHNOS 2014

Clinicians and researchers from Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University will present new findings from eight abstracts at the International Federation of Head and Neck Oncologic Societies World Congress being held July 26 - July 30 in New York. [More]
CFDA approves CASI's ENMD-2076 Phase II trial in triple-negative breast cancer patients

CFDA approves CASI's ENMD-2076 Phase II trial in triple-negative breast cancer patients

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that China's Food and Drug Administration has approved the Company's application to conduct a Phase II clinical trial in triple-negative breast cancer (TNBC) patients in China for its proprietary drug candidate, ENMD-2076. [More]
Metvix PDT now available at Odette Cancer Centre as additional treatment option for NMSC patients

Metvix PDT now available at Odette Cancer Centre as additional treatment option for NMSC patients

The Odette Cancer Centre at Sunnybrook Health Sciences Centre in conjunction with Galderma Canada are pleased to announce that Metvix PDT (Photodynamic Therapy), is now available at the Odette Cancer Centre in Toronto as an additional treatment option for patients with NMSC (non-melanoma skin cancer). [More]
Research demonstrates new computer software to help diagnose cancer cells

Research demonstrates new computer software to help diagnose cancer cells

In pathology, cells and cell nuclei are usually examined using a microscope for bio-marker expressions in tumours. This analysis is used to weigh up the treatment options for patients who have cancer, for example. [More]
Researchers develop new software to identify severity of cancer

Researchers develop new software to identify severity of cancer

Together with the company Tissuegnostics, the pathologist Lukas Kenner and his colleagues have developed a software that is able to identify cancer cells in tissue sections and demonstrate the presence of specific biomarkers on cells. The overall information provides a precise picture of the disease and leads to the most suitable treatment. [More]